Ligand Pharmaceuticals’ Post

Following our recent acquisition of Reach Separations, here’s what Peter Ridgway, Business Development Director at Reach Separations, had to say: "Becoming part of the CatSci Ltd Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset. As one of the founders of Reach Separations, I am delighted to join forces with CatSci to deliver strong growth and expand separation science into new marketplaces." This strategic acquisition marks a significant milestone for CatSci and enhances our ability to deliver programmes where rapid purification by chromatography is often essential to expediting clinical development. Together with Reach, we will drive forward our shared mission to deliver excellence in medicines development.   Learn more about how this acquisition will solve our customers' separation science challenges: https://lnkd.in/ebprErGt #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #DrugDevelopment #MedicinesDevelopment

Check out this webinar with Chris Dokomajilar on January 16th to see what the year may look like for biopharma dealmaking in 2024! #venturecapital #biotech #biopharma #pharma #dealmaking #2024predictions

Thoughts on this? >> Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech

Recursion is acquiring Exscientia for $688 million in stock. https://lnkd.in/gERzy4bQ This marks a big step up for Recursion's acquisitions, after acquiring smaller companies in 2023. Recursion acquired Cyclica (acquired by Recursion, Nasdaq: RXRX) and Valence Labs for $40 million and $47.5 million respectively. https://lnkd.in/g7iwHMRV As companies in the AI in drug discovery space consolidate, they will have access to more proprietary data and intellectual property. In order to get the most value from these acquisitions, there will need to be a greater focus on interoperability.

BGPartner advises Novo Holdings, EQT, OrbiMed and SR One on $100 mio Series C financing of Asceneuron SA Swiss biotech company Asceneuron SA successfully closed a $100 mio oversubscribed Series C financing round. The financing round was led by Novo Holdings with new investment from EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One Capital Management, alongside participation from existing investors Merck Serono S.p.A., Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. The funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease. BGPartner advised lead investor Novo Holdings as well as the investors EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One, on all Swiss legal matters and the negotiations of this Series C financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate). More information can be found here: https://lnkd.in/d278vevG More information about our legal and negotiation expertise can be found here: https://lnkd.in/eFQjD5fw #Financing #swiss #Biotech #law #negotiation #Alzheimer

There's advantage of having a seasoned Board to make smart #listing decisions. Today, American Oncology Network, Inc. (OTCQX: #AONC) finalized its voluntary switch from Nasdaq to the #OTCQX Best Market. The primary drivers behind the decision were lack of research coverage, low liquidity and excessive listing fees. Switching its listing to #OTCQX will allow the company to remain listed on a SEC recognized market, comply with U.S. Blue Sky exemptions, and continue to build its shareholder base. Thanks to Brian Lee and the Dentons team for a successful transition onto #OTCQX. Visit the company’s profile on our website to learn more: https://ow.ly/BIGR50Sc5wK #delisting #microcap #OTCMarkets

𝗪𝗲𝗲𝗸𝘀 𝗮𝗳𝘁𝗲𝗿 𝗰𝗹𝗼𝘀𝗶𝗻𝗴 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗱𝗲𝗮𝗹, 𝗞𝗮𝗿𝘂𝗻𝗮'𝘀 𝗲𝘅-𝗖𝗘𝗢 𝗵𝗲𝗮𝗱𝘀 𝘁𝗼 𝗕𝗹𝗮𝗰𝗸𝘀𝘁𝗼𝗻𝗲-𝗯𝗮𝗰𝗸𝗲𝗱 𝗔𝗻𝘁𝗵𝗼𝘀 How does Bill Meury celebrate a $14 billion merger? With a new post at a Blackstone-founded biotech. Meury has been appointed CEO at Anthos Therapeutics, just over a month after closing Karuna Therapeutics’ sale to Bristol Myers Squibb. He previously held senior roles at Allergan and Actavis (now Allergan). Anthos, which spun out of Novartis in 2019, is developing a next-generation blood thinner designed to prevent strokes and clots, but with lower risk of bleeding than current therapies. Recent Phase 2 results suggest a 150 mg dose of the candidate, abelacimab, reduced the risk of bleeding by 67% compared to Bayer and Johnson & Johnson’s blockbuster Xarelto in patients with atrial fibrillation. https://lnkd.in/euqnUDSd

Thoughts on this? >> Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

#nycannabis professionals, join our beta users who already loved aClassia and start building a thriving and compliant business! Book an appointment to learn more here: https://lnkd.in/ge_ejFfv #compliant #cannabis #ocmny

Fantastic series B fund raise to close out 2023! Exciting 2024 ahead for everyone at Sudo Biosciences as they take two of their best/first in class, next gen TYK2 inhibitors into clinic. #fundraise #researchanddevelopment #lifesciences #biotechnology #neurology #dermatology